COVID-19
ISARIC has been committed to provide a wide breadth of COVID-19 clinical research resources since the beginning of the outbreak. These resources are fully adaptable and completely free to use
The tools below aim to cover a range of tiers, suitable for different needs:
- Data collection only
- Contributing clinical data
- Research protocols
- Guidance to start your study
- ISARIC’s affiliated studies
Evidence & Reports
Tile subhead - Publications and Clinical data reports stemmed from the ISARIC COVID-19 clinical data platform.
COVID-19 CRF
Tile subhead - Collection of standardised clinical data.
Optional CRF Modules
Tile subhead - Modules to be used in addition to the Core or RAPID COVID-19 CRFs.
MIS-C in children and adolescents
Tile subhead - Stand alone CRF for children and adolescents.
Contributing data to the COVID-19 platform
Tile subhead - Secure data capture system that standardises global data on COVID-19.
Accessing COVID-19 clinical data
Tile subhead - Access ISARIC's data to generate and disseminate evidence.
ISARIC Partner Analysis
Tile subhead - Data analysis frequently asked questions.
Approved uses of platform data
Tile subhead - Current data research analyses.
Clinical data contributors
Tile subhead - Sites currently contributing to the clinical data platform.
Clinical Characterisation Protocol
Tile subhead - ISARIC/WHO protocol for standardised clinical data collection.
COVID-19 Long term protocol & survey
Tile subhead - Follow-up clinical data collection
COVID-19 CCP Global Toolkit
Tile subhead - Guidance on the Global Clinical Characterisation Protocol.
COVID-19 Rapid Evidence Reviews Group (CORRE)
Tile subhead - High quality rapid evidence synthesis for use in COVID-19 research.
Associated clinical studies in COVID-19
Tile subhead - Clinical data collection with the aims of building a research or study
Publication library
Visit this section to find ISARIC’s articles, studies and more.
Latest news
Women under 50 had worse long-term outcomes after hospitalisation with COVID-19
Women under 50 and people who experienced severe disease had worse long-term outcomes following hospitalisation with COVID-19.
Key inflammatory markers identified in COVID-19
ISARIC, supported by the UK Coronavirus Immunology Consortium (UK-CIC), has identified new biomarkers of inflammation that both indicate the severity of COVID-19 and distinguish it from severe influenza.
Long COVID: tackling a multifaceted condition requires a multi- disciplinary approach
The Lancet Infectious Diseases published the GloPID-R and ISARIC Long COVID Forum Working Group’ letter, describing the content and discussions of the Long COVID Forum which took place on 9-10 December 2020.